[1] Organization WH. International Agency for Research on Cancer GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lung Cancer. 2012. [Link]
[2] Gann PH. Risk factors for prostate cancer. Rev Urol. 2002; 4(Suppl 5):S3-S10. [PMID] [PMCID]
[3] Nogueira L, Corradi R, Eastham JA. Prostatic specific antigen for prostate cancer detection. Int Braz J Urol. 2009;35(5):521-9;530-2. [DOI: 10.1590/s1677-55382009000500003] [PMID]
[4] Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-8. [DOI: 10.1056/NEJMsr1606602] [PMID] [PMCID]
[5] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI: 10.3322/caac.21660] [PMID]
[6] Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477. [DOI: 10.1136/bmj.j477] [PMID] [PMCID]
[7] Ylli D, Sidhu S, Parikh T, Burman KD. Endocrine changes in obesity. Endotext [Internet]. 2022. [PMID]
[8] Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne). 2021;12:554078. [DOI: 10.3389/fendo.2021.554078] [PMID] [PMCID]
[9] Harrison S, Tilling K, Turner EL, Lane J, Simpkin A, Davis M, et al. Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful? Cancer Causes Control. 2016;27(12):1465-74. [DOI: 10.1007/s10552-016-0827-1] [PMID] [PMCID]
[10] Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane J, et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control. 2020;31(5):431-49. [DOI: 10.1007/s10552-020-01291-3] [PMID] [PMCID]
[11] Fowke JH, Matthews CE. PSA and body composition by dual X‐Ray absorptiometry (DXA) in NHANES. Prostate. 2010;70(2): 120-5. [DOI: 10.1002/pros.21039] [PMID]
[12] Lin D, Liu T, Chen L, Chen Z. Body mass index in relation to prostate-specific antigen-related parameters. BMC Urol. 2021;21(1):130. [DOI: 10.1186/s12894-020-00746-8] [PMID] [PMCID]
[13] Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71(5):787-91. [DOI: 10. 1016/j.urology.2007.11.036] [PMID]
[14] Bonn SE, Sjölander A, Tillander A, Wiklund F, Grönberg H, Bälter K. Body mass index in relation to serum prostate‐specific antigen levels and prostate cancer risk. Int J Cancer. 2016;139(1):50-7. [DOI: 10.1002/ijc.30052] [PMID]
[15] Popovici D, Stanisav C, Pricop M, Dragomir R, Saftescu S, Ciurescu D. Associations between Body Mass Index and Prostate Cancer: The Impact on Progression-Free Survival. Medicina (Kaunas). 2023;59(2):289. [DOI: 10.3390/medicina 59020289] [PMID] [PMCID]
[16] Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity‐related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298(19):2275-80. [DOI: 10.1001/jama.298.19.2275] [PMID]
[17] Grubb III RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009;18(3):748-51. [DOI: 10.1158/ 1055-9965.EPI-08-0938] [PMID]
[18] Zaza MM, Salem TA, Hassanin ISF, Soliman MHA. Effect of body mass index on prostate volume and prostate-specific antigen in men over 50: A cross-sectional study. Urologia. 2023;90(2):224-9. [DOI: 10.1177/03915603231163349] [PMID]
[19] Alcantara-Zapata DE, Thiersch M, Gonzales GF. Association of serum hepcidin with prostate-specific antigen levels in men from high Andean cities of Peru. Int J Health Sci (Qassim). 2023;17(2):28-36. [PMID] [PMCID]
[20] Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Labate AMM, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40(1):101-4. [DOI: 10.1016/0026-0495(91)90199-7] [PMID]
[21] Freedland SJ, Platz EA, Presti Jr JC, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175(2):500-4. [DOI: 10.1016/S0022-5347(05)001 62-X] [PMID]
[22] Giovannucci E, Rimm EB, Chute CG, Kawachi I ,Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140(11):989-1002. [DOI: 10.1093/oxford journals.aje.a117206] [PMID]
[23] Porcaro AB, Tafuri A, Sebben M, Processali T, Pirozzi M, Amigoni N, et al. Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection. Minerva Urol Nefrol. 2019;71(5):516-23. [DOI: 10.23736/S0393-2249.19.03401-5] [PMID]
[24] Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St. Sauver JL, Jacobsen SJ, et al. The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev. 2011;20(3):501-8. [DOI: 10.1158/ 1055-9965.EPI-10-1006] [PMID] [PMCID]
[25] Benson M, McMahon D, Cooner W, Olsson C. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol. 1993;11(4):206-13. [DOI: 10.1007/ BF00185070] [PMID]
[26] Omri N, Kamil M, Alexander K, Edmond S, Ariel Z, David K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume.
298
Shojaei S, et al. Prostate-specific Antigen and Body Mass Index JSMJ. 2023; 22(5):???-???
Jundishapur
Journal of Medical Sciences
November & December 2024. Vol 22. No 5
Prostate. 2020;80(16):1444-9. [DOI: 10.1002/pros.24078] [PMID]
[27] Coric J, Mujic J, Kucukalic E, Ler D. Prostate-Specific Antigen (PSA) and prostate volume: better predictor of prostate cancer for bosnian and herzegovina men. Open Biochem J. 2015;9:34-6. [DOI: 10.2174/1874091X01509010034] [PMID] [PMCID]
[28] Putra IBO, Hamid AR, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate Int. 2016;4(2):43-8. [DOI: 10.1016/j.prnil.2016.03.002] [PMID]
[29] Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005;40(3):121-8. [DOI: 10.1016/j.exger.2004.12.008] [PMID]
[30] Baruah S, Nath S, Puthenveetil R, Baruah S, Deka P, Bawri B. Correlation of age, prostate volume, serum prostate-specific antigen, and serum testosterone in Indian, benign prostatic hyperplasia patients. UroToday Int J. 2012;5(5):1-6. [DOI: 10.3834/uij.1944-5784.2012.10.02]
[31] Vesely S, Knutson T, Damber J-E, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003;37(4):322-8. [DOI: 10.1080/00365590310014760] [PMID]
[32] Lee SE, Chung JS, Han BK, Moon KH, Hwang SI, Lee HJ, et al. Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology. 2008;71(3):395-8. [DOI: 10.1016/j. urology.2007.10.019] [PMID]
[33] Putra IBO, Hamid AR, Mochtar CA, Umbas R. Prostate International. Age (y). 2016;65:7.81.
[34] Liu C-C, Huang S-P, Li W-M, Wang C-J, Chou Y-H, Li C-C, et al. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology. 2007;70(4):677-80. [DOI: 10.1016/j.urology.2007.05.025] [PMID]
[35] Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, et al. Benign prostatic hyperplasia and its aetiologies. European Urology Supplements. 2009;8(13):865-71. [DOI: 10.1016%2Fj.eursup.2009.11.002 ]
[36] Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia (BPH). BJU Int. 2008;102(5):536-44. [DOI: 10.1111/j.1464-410X.2008. 07667.x] [PMID]
[37] Payne H, Cornford P, editors. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol. 2011;29(6):593-601. [DOI: 10.1016/j.urolonc.2009.11.003] [PMID]
[38] Lieber MM, Jacobsen SJ, Roberts RO, Rhodes T, Girman CJ. Prostate volume and prostate‐specific antigen in the absence of prostate cancer: A review of the relationship and prediction of long‐term outcomes. Prostate. 2001;49(3):208-12. [DOI: 10.1002/pros.1136] [PMID]
)